Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as Adjuvant Therapy for Triple-Negative Breast Cancer
NCT02954874Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Started Jan 2017; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02954874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954874.